Saturday 17 October 2026
Export SEELQ’s income statement to Excel — free account
Seelos Therapeutics, Inc.
SEELQ Healthcare Biotechnology
Seelos Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $2.2 million. Revenue growth for three consecutive years, operating cash flow growth for three.
0.00
0.00
NaN
Follow SEELQ
| Older periods | Sep '23 | Dec '23 | Mar '24 | Jun '24 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
453.43% | 171.72% | 100.87% | (10.86%) | |
| (218.66%) | (269.01%) | (198.99%) | 57.34% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
175.32% | 113.00% | 81.76% | (14.52%) | |
Average Days of Receivables |
41.90 | 126.42 | 178.99 | 34.07 | |
Free Cash Flow per Share |
(996.90) | (624.33) | (179.19) | (84.76) | |
Free Cash Flow |
(35.09) | (23.91) | (18.21) | (13.27) | |
| Other line items | |||||
Cash ROIC |
132.29% | 78.36% | 55.88% | 47.68% | |
Accounts Receivable Turnover |
4.24 | 3.80 | 2.24 | 6.51 | |
Accounts Payable Turnover |
0.01 | 0.00 | 0.00 | 0.00 | |
Inventory Turnover |
0.00 | — | — | — | |
Average Days of Payables |
35,808.42 | 0.00 | 0.00 | 0.00 | |
Days of Inventory on Hand |
0.00 | — | — | — | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
2,062.55% | 1,367.09% | 1,417.12% | 1,014.45% | |
Selling, General and Administrative Expense of Revenue |
654.08% | 571.27% | 588.75% | 565.59% | |
Share Based Compensation of Revenue |
204.21% | 181.03% | 196.61% | 186.94% | |
Interest Coverage |
(329.51) | (539.99) | (413.43) | (278.58) | |
Operating CF/Net income |
0.69 | 0.63 | 0.67 | (3.24) | |
Depreciation/Fixed assets |
0.00 | — | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | — | 0.00 | 0.00 | |
Revenue per Share |
54.69 | 57.52 | 19.43 | 12.86 | |
Operating CF per Share |
(996.90) | (624.33) | (179.19) | (84.76) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates